A Combination of Benmelstobart, Anlotinib, and Chemotherapy Improves Survival Rates in SCLC, Study Suggests
kalhh / Pixabay

A Combination of Benmelstobart, Anlotinib, and Chemotherapy Improves Survival Rates in SCLC, Study Suggests

  Advancing patient outcomes hinges on the development of targeted treatments, particularly in conditions with grim prognoses such as small cell lung cancer (SCLC), which typically has a life expectancy…

Continue Reading A Combination of Benmelstobart, Anlotinib, and Chemotherapy Improves Survival Rates in SCLC, Study Suggests
Does Antireflux Surgery for Barrett’s Esophagus Change Esophageal Cancer Risk? 
source: shutterstock.com

Does Antireflux Surgery for Barrett’s Esophagus Change Esophageal Cancer Risk? 

  Barrett's esophagus (BE) is a condition in which the cells in your esophagus undergo a transformation, becoming more like intestinal cells. Although doctors aren't entirely certain why this change…

Continue Reading Does Antireflux Surgery for Barrett’s Esophagus Change Esophageal Cancer Risk? 
Researchers Track Gene Therapy’s Impact on Neural Connections in Hurler Syndrome
source: shutterstock.com

Researchers Track Gene Therapy’s Impact on Neural Connections in Hurler Syndrome

617 words (source - 3% match) vs. 452 words (mine - 4% match) As our healthcare field continues to innovate and grow, we have seen more conversations regarding gene therapy…

Continue Reading Researchers Track Gene Therapy’s Impact on Neural Connections in Hurler Syndrome
Rare Community Profiles: Understanding MAC Lung Disease, Bronchiectasis, and PAH: A Discussion with Dr. Martina Flammer
source: pixabay.com

Rare Community Profiles: Understanding MAC Lung Disease, Bronchiectasis, and PAH: A Discussion with Dr. Martina Flammer

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: Understanding MAC Lung Disease, Bronchiectasis, and PAH: A Discussion with Dr. Martina Flammer
Belzutifan Improves Progression-Free Survival for Renal Cell Carcinoma Over Everolimus
source: shutterstock.com

Belzutifan Improves Progression-Free Survival for Renal Cell Carcinoma Over Everolimus

The Phase 3 LITESPARK-005 trial sought to understand whether Welireg (belzutifan) was effective in treating advanced renal cell carcinoma (RCC) when compared to other treatments, such as everolimus. According to…

Continue Reading Belzutifan Improves Progression-Free Survival for Renal Cell Carcinoma Over Everolimus

Glofitamab with Obinutuzumab Shows Promise in Heavily Pretreated Richter Syndrome

Also known as Richter’s Transformation, Richter syndrome is a rare and aggressive complication of chronic lymphocytic leukemia (CLL). When someone develops Richter syndrome, their CLL can transform into another rare…

Continue Reading Glofitamab with Obinutuzumab Shows Promise in Heavily Pretreated Richter Syndrome
Phase 2b Clinical Study Begins to Evaluate Bexotegrast for IPF
kalhh / Pixabay

Phase 2b Clinical Study Begins to Evaluate Bexotegrast for IPF

  The U.S. FDA has approved two treatments for people living with idiopathic pulmonary fibrosis (IPF). These therapies—Esbriet (pirfenidone) and Ofev (nintedanib)—both work to reduce fibrosis, or scarring, in the…

Continue Reading Phase 2b Clinical Study Begins to Evaluate Bexotegrast for IPF
FDA Clears Global Phase 3 Study of Lisaftoclax for Previously Treated CLL or SLL
Source: https://pixabay.com/en/white-blood-cell-cell-blood-cell-543471/

FDA Clears Global Phase 3 Study of Lisaftoclax for Previously Treated CLL or SLL

  In Jordyn Sava's reporting from Targeted Oncology, readers learn that the U.S. Food and Drug Administration (FDA) granted clearance to a global Phase 3 study. This means that the…

Continue Reading FDA Clears Global Phase 3 Study of Lisaftoclax for Previously Treated CLL or SLL
Study Results Available on Dexpramipexole for Eosinophilic Asthma
source: shutterstock.com

Study Results Available on Dexpramipexole for Eosinophilic Asthma

  The Phase 2 EXHALE-1 clinical trial, initiated by clinical-stage biotechnology company Areteia Therapeutics, Inc. ("Areteia"), sought to understand how safe, effective, and well-tolerated dexpramipexole was in reducing symptoms of…

Continue Reading Study Results Available on Dexpramipexole for Eosinophilic Asthma

CB-010 Shows Promise for B-Cell Non-Hodgkin Lymphoma, Study Shows

Recent results are available from the dose escalation portion of the Phase 1 ANTLER study. In reporting from Targeted Oncology, Jordyn Sava shares that the study included 16 participants living…

Continue Reading CB-010 Shows Promise for B-Cell Non-Hodgkin Lymphoma, Study Shows
Mavorixafor is Safe and Effective for Treating WHIM Syndrome, Trial Data Suggests
JerzyGorecki / Pixabay

Mavorixafor is Safe and Effective for Treating WHIM Syndrome, Trial Data Suggests

  In the past, treatment for WHIM syndrome has focused on symptom management: treating infections and myelokathexis with antibiotics or granulocyte colony stimulating factor. Infusion can treat hypogammaglobulinemia and surgery…

Continue Reading Mavorixafor is Safe and Effective for Treating WHIM Syndrome, Trial Data Suggests
Positive Data Available from Phase 4 Trial for Primary Immunodeficiencies
allinonemovie / Pixabay

Positive Data Available from Phase 4 Trial for Primary Immunodeficiencies

  In a late July 2023 news release, global healthcare company Grifols shared that positive topline data was now available from a Phase 4 clinical study evaluating XEMBIFY (immune globulin…

Continue Reading Positive Data Available from Phase 4 Trial for Primary Immunodeficiencies